wild/tyrosine

CROSS REFERENCES TO RELATED APPLICATIONS The present application claims priority to Japanese Priority Patent Application JP 2010-016675 filed in the Japan Patent Office on Jan. 28, 2010, the entire contents of which are hereby incorporated by reference. BACKGROUND The present application relates to

BACKGROUND OF THE INVENTION 1. Field of The Invention This invention relates generally to the molecular cloning of genes which can be used in toxicity assays and, specifically, to the isolation of a mammalian DNA recombination and repair gene which can be used in an assay to screen various

FIELD OF THE INVENTION The present invention relates to a process for the production of vitamin E by growing organisms, in particular plants, which have an increased tyrosine aminotransferase activity over the wild type, and to the genetically modified organisms, in particular plants,

STATEMENT REGARDING FEDERALLY-SPONSORED R&D Not applicable REFERENCE TO MICROFICHE APPENDIX Not applicable FIELD OF THE INVENTION The invention is directed to the field of transgenic mice containing a disrupted PTP-1B gene. The mice may contain a disruption in either one or both copies of the

This application incorporates a 502 KB text file named "seqlst00631" created Jul. 22, 2010, which is the sequence listing for this application. TECHNICAL FIELD OF THE INVENTION This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug

TECHNICAL FIELD OF THE INVENTION This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug discovery, target discovery, clinical testing for cancer. BACKGROUND OF THE INVENTION Phosphorylation of tyrosine residues is a central feature of most

BACKGROUND OF THE INVENTION Asthma and rhinitis are atopic (allergic) diseases affecting between 20-30% of the population. They are associated with acute and chronic inflammatory responses resulting from contact with protein particles in the environment. Initially, exposure of the airway immune

NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT Not Applicable. BACKGROUND OF THE INVENTION Field of the Invention The present disclosure relates to the fields of molecular biology, ophthalmology, and gene therapy. In particular embodiments, capsid-mutated rAAV vectors and methods for their use

TECHNICAL FIELD The present invention relates to: a monoclonal antibody being capable of binding to transforming growth factor alpha (hereinafter referred to as "TGF-.alpha.") and having an effect of suppressing in vivo growth of cancer cells having a mutated Ras protein; and an anti-cancer agent

BACKGROUND OF THE INVENTION The present invention relates to sweet proteins. Specifically, this invention relates to Brazzein protein that has been modified to provide a candy-like taste with high potency. The most widely used natural sweetener, sugar (sucrose), has significant problems associated

BACKGROUND OF THE INVENTION The present invention relates to sweet proteins. Specifically, this invention relates to Brazzein protein that has been modified to provide a candy-like taste with high potency. The most widely used natural sweetener, sugar (sucrose), has significant problems associated

BACKGROUND OF THE INVENTION Kinases, which constitute a large family of enzymes (>500 in humans), catalyze the transfer of the .gamma.-phosphate of ATP to protein substrates. Reversible phosphorylation plays a paramount role in cell signaling processes and is regulated by kinases and

BACKGROUND OF THE INVENTION Field of the Invention Major advances in the field of gene therapy have been achieved by using viruses to deliver therapeutic genetic material. The adeno-associated virus (AAV) has attracted considerable attention as a highly effective viral vector for gene therapy due to

BACKGROUND OF INVENTION Major advances in the field of gene therapy have been achieved by using viruses to deliver therapeutic genetic material. The adeno-associated virus (AAV) has attracted considerable attention as a highly effective viral vector for gene therapy due to its low immunogenicity and

BACKGROUND OF THE INVENTION Field of the Invention Major advances in the field of gene therapy have been achieved by using viruses to deliver therapeutic genetic material. The adeno-associated virus (AAV) has attracted considerable attention as a highly effective viral vector for gene therapy due to